Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07846527
Recruiting Observational

Vaginal Wall Retraction Using VuSleeve

NCT07846527 · tracked via the Priya Life Science USA tracker
Sponsor
Ceek Women's Health, INC
Phase
Observational
Started
2026-09
Last updated
2026-09-29

Condition(s) studied

Adult Females

Study summary

This is a post-market, observational, non-interventional, single group/cohort study in which participants already have a scheduled gynecological exam and/or procedure. The goal of this study is to obtain investigator perspectives on using VuSleeve for routine gynecological care. Investigator perspectives from this mixed-method study will be captured through quantitative and qualitative components.

Eligibility

Sex
FEMALE
Min age
21 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Subject was assigned female at birth * Subject is 21 - 65 years of age, inclusive, at the time of exam or procedure * Subject is undergoing a gynecological exam and/or procedure * Subject has undergone one or more prior gynecological exams Exclusion Criteria: * Subject is pregnant * Subject has stated or documented history of vaginal dysplasia or vaginismus

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
UCHealth Anschutz Aurora Colorado Recruiting
Denver Health Denver Colorado Recruiting
Emory University Atlanta Georgia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07846527 on ClinicalTrials.gov ↗ ← All trials in the USA